研究性三价B群链球菌疫苗全液体与冻干剂型在健康非妊娠女性中的安全性和免疫原性:一项随机对照II期试验结果
这项II期随机对照观察者盲试验纳入18-40岁健康非妊娠女性,分别接种单剂全液体(n=529)或冻干(n=521)三价GBS疫苗。两种剂型不良事件报告率相似,严重不良事件分别为6例(1.1%)和9例(1.7%),均未判定与接种相关或致死。接种后31天,两种剂型三个血清型特异性IgG几何平均浓度比值(液体/冻干)的95%CI均落在预设(0.5,2.0)区间内,证明全液体剂型与冻干剂型免疫原性等效。
要点
- 全液体与冻干三价GBS疫苗在健康非妊娠女性中安全性和免疫原性相似。
- 接种后31天,三个血清型IgG GMC比值(液体/冻干)95%CI均在预设等效区间内。
- 严重不良事件发生率:全液体组1.1%(6例)vs 冻干组1.7%(9例),均未判定与接种相关或致死。
核心结论
- 两种剂型的研究性三价GBS疫苗安全性良好,诱导的GBS血清型特异性抗体浓度相似。
- 在健康非妊娠女性中,全液体剂型在三个血清型免疫原性方面均等效于冻干剂型。
研究设计与样本
- II期、随机、对照、观察者盲试验,纳入18-40岁健康非妊娠女性。
- 受试者于第1天接种单剂全液体(n=529)或冻干(n=521)三价GBS疫苗。
- 安全性评估至第181天(研究终止);第1天(接种前)和第31天检测血清型Ia/Ib/III特异性IgG抗体。
- 等效性判定标准:第31天几何平均浓度(GMC)比值(液体/冻干)的双侧95%CI在每个血清型均落在(0.5, 2.0)区间内。
主要发现
- 两种剂型报告的征集性和非征集性不良事件发生率相似。
- 严重不良事件:全液体GBS组6例(1.1%),冻干GBS组9例(1.7%),均未判定与接种相关或致死。
- 第31天时,两组血清型特异性IgG浓度均较第1天升高8-16倍。
- 接种后30天,GMC比值(液体/冻干)的95%CI均在预设区间内:血清型Ia为1.02(95%CI:0.79, 1.32),血清型Ib为0.93(0.71, 1.21),血清型III为0.99(0.76, 1.30)。
关键数值与推荐
- 等效性判定标准:第31天GMC比值(液体/冻干)的双侧95%CI在每个血清型均落在(0.5, 2.0)区间内。
- 血清型Ia GMC比值(液体/冻干)1.02(95%CI:0.79, 1.32)。
- 血清型Ib GMC比值(液体/冻干)0.93(95%CI:0.71, 1.21)。
- 血清型III GMC比值(液体/冻干)0.99(95%CI:0.76, 1.30)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We evaluated the safety and immunogenicity of liquid and lyophilized formulations of an investigational trivalent group B streptococcus (GBS) vaccine in non-pregnant women and assessed the formulations' equivalence in terms of serotype-specific immune response. METHODS: This phase II, randomized, comparative, observer-blind trial enrolled healthy non-pregnant women 18-40 years of age. Women received a single dose of fully liquid (n = 529) or lyophilized (n = 521) trivalent GBS vaccine on day 1. Safety assessments were performed up to day 181 (study termination). Serotype Ia/Ib/III-specific immunoglobulin G (IgG) antibodies were measured in sera from women on day 1 (pre-vaccination) and day 31. Equivalence between the two formulations was demonstrated if the two-sided 95% confidence interval (CI) for the ratio (liquid/lyophilized) of the geometric mean concentrations (GMCs) on day 31 was contained in a (0.5, 2.0) interval for each serotype. RESULTS: Solicited and unsolicited adverse events were reported at similar rates for both formulations. Serious adverse events were reported for six (1.1%) liquid GBS and nine (1.7%) lyophilized GBS vaccinated women, none of which were considered related to vaccination or fatal. On day 31, serotype-specific IgG concentrations were 8-16-fold higher than on day 1 in both groups. Equivalence of the liquid to the lyophilized formulation 30 days post-vaccination was demonstrated as the 95% CIs of the GMC ratios were within the pre-specified interval for the three serotypes: GMC ratios were 1.02 (95% CI: 0.79, 1.32) for serotype Ia, 0.93 (0.71, 1.21) for serotype Ib and 0.99 (0.76, 1.30) for serotype III. CONCLUSIONS: Both formulations of the investigational trivalent GBS vaccine had favorable safety profiles and induced similar GBS serotype-specific antibody concentrations. This study demonstrated that the fully liquid formulation was equivalent to the lyophilized formulation in healthy non-pregnant women in terms of immunogenicity for all three serotypes. CLINICAL TRIALS REGISTRATION: NCT02270944.
引用
- Beran J, Leroux-Roels G, Van Damme P, et al. Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial. Vaccine. 2020. PMID: 32169390. doi:10.1016/j.vaccine.2020.02.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。